Sanford C. Bernstein Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) Stock

Insulet (NASDAQ:PODD) had its price target increased by stock analysts at Sanford C. Bernstein from $175.00 to $200.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Sanford C. Bernstein‘s target price suggests a potential upside of 29.03% from the stock’s current price.

A number of other research firms also recently weighed in on PODD. Robert W. Baird set a $175.00 price target on shares of Insulet in a research note on Thursday, August 6th. Stifel Nicolaus reduced their price objective on Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Citigroup boosted their target price on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Truist Financial lowered Insulet from a “buy” rating to a “hold” rating and dropped their target price for the stock from $210.00 to $153.00 in a research report on Wednesday, August 5th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Insulet in a research note on Wednesday. Thirteen research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Insulet presently has an average rating of “Hold” and a consensus price target of $189.20.

Insulet Stock Down 6.1%

PODD traded down $10.02 on Thursday, reaching $155.00. 503,801 shares of the company traded hands, compared to its average volume of 1,394,040. The stock’s 50 day moving average price is $141.65 and its 200-day moving average price is $178.00. Insulet has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a market cap of $10.75 billion, a price-to-earnings ratio of 28.93, a PEG ratio of 1.22 and a beta of 1.06. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. During the same quarter in the prior year, the firm earned $1.24 EPS. The company’s revenue was up 19.2% compared to the same quarter last year. On average, sell-side analysts expect that Insulet will post 6.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PODD. BlackRock Inc. bought a new stake in Insulet during the second quarter worth approximately $1,018,582,000. Arrowstreet Capital Limited Partnership raised its position in shares of Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the period. Man Group plc bought a new position in shares of Insulet in the second quarter valued at approximately $78,746,000. Bank of America Corp DE bought a new position in shares of Insulet in the second quarter valued at approximately $64,921,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Insulet in the second quarter worth $60,615,000.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q3 results topped expectations: Insulet reported adjusted EPS of $1.99 versus the $1.59 consensus and revenue of $842 million versus estimates of about $833 million. Revenue grew 19.2% year over year. Insulet Q3 earnings and revenues surpass estimates
• Positive Sentiment: $1 billion share buyback: The repurchase authorization may support demand for shares. Insulet also raised its 2026 outlook, although reports indicate its full-year EPS outlook was maintained. Insulet announces a $1 billion equity buyback
• Neutral Sentiment: Wells Fargo raised its target to $172 from $144 but kept an “equal weight” rating, suggesting the analyst sees some potential upside without making a bullish call. Wells Fargo raises Insulet price target
• Negative Sentiment: 2027 growth risks: The CEO expects slower growth next year and anticipates rivals will take some share from the Omnipod business. Those comments could weigh on expectations despite the strong quarter. CEO discusses slower growth and competition

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.